Akero Therapeutics, Inc. AKRO
At closeDec 9, 2025, 4:00 PM EST
After hours · Dec 9, 4:00 PM ET
- YTD
- +96.44%
- 1 year
- +75.67%
- Market cap
- 4.50B
- EPS (ttm)
- -1.94
- P/E ratio
- -29.54
- YTD return
- +96.44%
- 1-year return
- +75.67%
- Volume
- 11.61M
- Avg volume
- 2.29M
- Open
- 54.52
- Previous close
- 54.65
- Day's range
- 54.52 – 54.65
- 52-week range
- 53.84 – 54.83
- Beta
- -0.40
YTD +26.57 (+94.62%)
Key statistics
- Enterprise value
- 4.32B
- PEG ratio
- -131.55
- Price / sales
- 0.00
- Price / book
- 4.68
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -15.33%
Analyst view
- Strong buy9
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.9333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2025 | Sep 30, 2025 | -0.94 | -0.99 | -0.05 | -5.32% |
| Aug 8, 2025 | Jun 30, 2025 | -0.97 | -0.86 | +0.11 | +11.34% |
| May 12, 2025 | Mar 31, 2025 | -1.01 | 0.90 | +1.91 | +189.11% |
| Feb 28, 2025 | Dec 31, 2024 | -0.98 | -0.99 | -0.01 | -1.02% |
| Nov 8, 2024 | Sep 30, 2024 | -0.90 | -1.05 | -0.15 | -16.67% |
| Aug 9, 2024 | Jun 30, 2024 | -0.90 | -0.81 | +0.09 | +10.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 10, 2025 | Wolfe Research | down | Outperform | Peer Perform |
| Oct 10, 2025 | HC Wainwright & Co. | down | Buy | Neutral |
| Oct 9, 2025 | Jefferies | down | Buy | Hold |
| Oct 9, 2025 | Canaccord Genuity | down | Buy | Hold |
| Aug 4, 2025 | TD Cowen | init | — | Buy |
| May 27, 2025 | B of A Securities | main | Buy | Buy |
About Akero Therapeutics, Inc.
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 69
- Website
- akerotx.com
News
NextCure To Merge With Avere Therapuetics In All-Stock Deal; NXTC Holders To Receive A Contingent Value Right For 90% Of Net Proceeds From Any Future License, Divestiture Or Monetization Of Its Pipeline Assets And Programs For Two Years; NXTC Also Announces $320M Private Placement 
Bourgeon Capital Management LLC Takes Position in Akero Therapeutics, Inc. $AKRO 
Corient Private Wealth LLC Takes $3.93 Million Position in Akero Therapeutics, Inc. $AKRO 
Alkeon Capital Management LLC Grows Stake in Akero Therapeutics, Inc. $AKRO 
Novo Nordisk has completed its acquisition of Akero Therapeutics 
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO 
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO) 
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025 
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO) 
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
Your note
Sign in to keep a note on AKRO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHENG ANDREW | Chief Executive Officer | Stock Gift | Nov 19, 2025 | 436,837 |
| GANGLOFF SCOTT A. | Chief Technology Officer | Conversion of Exercise of derivative security | Aug 14, 2025 | 26,351 |
| GRAHAM G. WALMSLEY | Director | Conversion of Exercise of derivative security | Oct 7, 2025 | 1,293,000 |
| HENDERSON JANE | Director | Conversion of Exercise of derivative security | Aug 11, 2025 | 9,398 |
| IWICKI MARK T. | Director | Stock Award(Grant) | Jun 2, 2025 | 9,398 |
| LAMY PATRICK D | Officer | Sale | Jun 30, 2025 | 29,891 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| HHG PLC | 8.42% | 6,738,556 | 0 | Jun 29, 2025 |
| BlackRock Inc | 7.23% | 5,779,412 | 0 | Jun 29, 2025 |
| General Atlantic Llc | 7.17% | 5,733,989 | 0 | Jun 29, 2025 |
| RTW INVESTMENTS, LLC | 6.85% | 5,477,561 | 0 | Jun 29, 2025 |
| Vanguard Group Inc | 5.66% | 4,529,628 | 0 | Jun 29, 2025 |
| T. Rowe Price Associates, Inc. | 5.64% | 4,509,325 | 0 | Jun 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 3.01% | 2,411,506 | 0 | Jul 30, 2025 |
| iShares Russell 2000 ETF | 2.11% | 1,684,321 | 0 | Aug 30, 2025 |
| US Small-Cap Growth II Equity Comp | 2.03% | 1,626,094 | 0 | Jun 29, 2025 |
| Janus Henderson Global Life Sciences | 1.80% | 1,436,176 | 0 | Jun 29, 2025 |
| Janus Henderson Global Life Sciences D | 1.80% | 1,436,176 | 0 | Jun 29, 2025 |
| T. Rowe Price New Horizons | 1.68% | 1,340,893 | 0 | Jul 30, 2025 |